Mineralys Therapeutics, Common Stock Technical Analysis
| MLYS Stock | 11.87 0.73 5.79% |
As of the 22nd of November, Mineralys Therapeutics, secures the Mean Deviation of 2.62, downside deviation of 3.53, and Risk Adjusted Performance of 0.077. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Mineralys Therapeutics,, as well as the relationship between them. Please verify Mineralys Therapeutics, standard deviation, value at risk, as well as the relationship between the Value At Risk and kurtosis to decide if Mineralys Therapeutics, Common is priced some-what accurately, providing market reflects its recent price of 11.87 per share. Given that Mineralys Therapeutics, has jensen alpha of 0.1119, we recommend you to check Mineralys Therapeutics,'s last-minute market performance to make sure the company can sustain itself at a future point.
Mineralys Therapeutics, Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Mineralys, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to MineralysMineralys |
Mineralys Therapeutics, Analyst Consensus
| Target Price | Advice | # of Analysts | |
| 35.75 | Strong Buy | 8 | Odds |
Most Mineralys analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Mineralys stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Mineralys Therapeutics,, talking to its executives and customers, or listening to Mineralys conference calls.
Mineralys Therapeutics, technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Mineralys Therapeutics, Technical Analysis
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of Mineralys Therapeutics, volatility. High ATR values indicate high volatility, and low values indicate low volatility.
Mineralys Therapeutics, Trend Analysis
Use this graph to draw trend lines for Mineralys Therapeutics, Common. You can use it to identify possible trend reversals for Mineralys Therapeutics, as well as other signals and approximate when it will take place. Remember, you need at least two touches of the trend line with actual Mineralys Therapeutics, price movement. To start drawing, click on the pencil icon on top-right. To remove the trend, use eraser icon.Mineralys Therapeutics, Best Fit Change Line
The following chart estimates an ordinary least squares regression model for Mineralys Therapeutics, Common applied against its price change over selected period. The best fit line has a slop of 0.03 , which means Mineralys Therapeutics, Common will continue generating value for investors. It has 122 observation points and a regression sum of squares at 33.88, which is the sum of squared deviations for the predicted Mineralys Therapeutics, price change compared to its average price change.About Mineralys Therapeutics, Technical Analysis
The technical analysis module can be used to analyzes prices, returns, volume, basic money flow, and other market information and help investors to determine the real value of Mineralys Therapeutics, Common on a daily or weekly bases. We use both bottom-up as well as top-down valuation methodologies to arrive at the intrinsic value of Mineralys Therapeutics, Common based on its technical analysis. In general, a bottom-up approach, as applied to this company, focuses on Mineralys Therapeutics, price pattern first instead of the macroeconomic environment surrounding Mineralys Therapeutics,. By analyzing Mineralys Therapeutics,'s financials, daily price indicators, and related drivers such as dividends, momentum ratios, and various types of growth rates, we attempt to find the most accurate representation of Mineralys Therapeutics,'s intrinsic value. As compared to a bottom-up approach, our top-down model examines the macroeconomic factors that affect the industry/economy before zooming in to Mineralys Therapeutics, specific price patterns or momentum indicators. Please read more on our technical analysis page.
| 2023 | 2024 (projected) | Current Ratio | 23.76 | 24.95 | Net Debt To EBITDA | 0.58 | 0.55 |
Mineralys Therapeutics, November 22, 2024 Technical Indicators
Most technical analysis of Mineralys help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Mineralys from various momentum indicators to cycle indicators. When you analyze Mineralys charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.077 | |||
| Market Risk Adjusted Performance | 0.139 | |||
| Mean Deviation | 2.62 | |||
| Semi Deviation | 3.25 | |||
| Downside Deviation | 3.53 | |||
| Coefficient Of Variation | 1092.14 | |||
| Standard Deviation | 3.73 | |||
| Variance | 13.9 | |||
| Information Ratio | 0.066 | |||
| Jensen Alpha | 0.1119 | |||
| Total Risk Alpha | (0.09) | |||
| Sortino Ratio | 0.0697 | |||
| Treynor Ratio | 0.129 | |||
| Maximum Drawdown | 20.98 | |||
| Value At Risk | (5.67) | |||
| Potential Upside | 6.27 | |||
| Downside Variance | 12.44 | |||
| Semi Variance | 10.53 | |||
| Expected Short fall | (2.72) | |||
| Skewness | 0.477 | |||
| Kurtosis | 2.34 |
Mineralys Therapeutics, November 22, 2024 Daily Trend Indicators
Traders often use several different daily volumes and price technical indicators to supplement a more traditional technical analysis when analyzing securities such as Mineralys stock. With literally thousands of different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 18,028 | ||
| Daily Balance Of Power | (0.73) | ||
| Rate Of Daily Change | 0.94 | ||
| Day Median Price | 12.28 | ||
| Day Typical Price | 12.14 | ||
| Price Action Indicator | (0.78) |
Additional Tools for Mineralys Stock Analysis
When running Mineralys Therapeutics,'s price analysis, check to measure Mineralys Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mineralys Therapeutics, is operating at the current time. Most of Mineralys Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Mineralys Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mineralys Therapeutics,'s price. Additionally, you may evaluate how the addition of Mineralys Therapeutics, to your portfolios can decrease your overall portfolio volatility.